Elevation of substance P-like peptides in the CSF of psychiatric patients - PubMed (original) (raw)
- PMID: 6203562
Elevation of substance P-like peptides in the CSF of psychiatric patients
R Rimón et al. Biol Psychiatry. 1984 Apr.
Abstract
Using a radioimmunoassay procedure substance P-like activity was measured in samples of human CSF obtained from 12 patients with major depressive disorder, 12 with schizophrenia, and 15 control cases diagnosed as psychiatrically normal. Levels were significantly higher in CSF of patients with depressive disorder as compared with schizophrenic patients or controls. Chemical characterization revealed that the measured activity was less basic than substance P itself and might be due to C-terminal fragments. A component reacting with an antiserum highly specific for the substance P[1-7]fragment was found in CSF of patients with depressive disorder. The results indicate that substance P-related peptides may be biological markers in psychoses, particularly in major depressive disorder.
Similar articles
- CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).
Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, Benzer A, Winkler H. Miller C, et al. Biol Psychiatry. 1996 Jun 1;39(11):911-8. doi: 10.1016/0006-3223(95)00098-4. Biol Psychiatry. 1996. PMID: 9162202 Clinical Trial. - Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively.
Widerlöv E, Lindström LH, Wahlestedt C, Ekman R. Widerlöv E, et al. J Psychiatr Res. 1988;22(1):69-79. doi: 10.1016/0022-3956(88)90030-1. J Psychiatr Res. 1988. PMID: 3397912 - Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders.
Bissette G, Widerlöv E, Walléus H, Karlsson I, Eklund K, Forsman A, Nemeroff CB. Bissette G, et al. Arch Gen Psychiatry. 1986 Dec;43(12):1148-51. doi: 10.1001/archpsyc.1986.01800120034008. Arch Gen Psychiatry. 1986. PMID: 3778111 - CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder.
Hou C, Jia F, Liu Y, Li L. Hou C, et al. Brain Res. 2006 Jun 20;1095(1):154-8. doi: 10.1016/j.brainres.2006.04.026. Epub 2006 May 19. Brain Res. 2006. PMID: 16713589
Cited by
- Future prospects in depression research.
Holtzheimer PE 3rd, Nemeroff CB. Holtzheimer PE 3rd, et al. Dialogues Clin Neurosci. 2006;8(2):175-89. doi: 10.31887/DCNS.2006.8.2/pholtzheimer. Dialogues Clin Neurosci. 2006. PMID: 16889104 Free PMC article. Review. - Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I, Lieb K. Herpfer I, et al. CNS Drugs. 2005;19(4):275-93. doi: 10.2165/00023210-200519040-00001. CNS Drugs. 2005. PMID: 15813642 Review. - Advances in the treatment of depression.
Holtzheimer PE 3rd, Nemeroff CB. Holtzheimer PE 3rd, et al. NeuroRx. 2006 Jan;3(1):42-56. doi: 10.1016/j.nurx.2005.12.007. NeuroRx. 2006. PMID: 16490412 Free PMC article. Review. - The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.
Pantaleo N, Chadwick W, Park SS, Wang L, Zhou Y, Martin B, Maudsley S. Pantaleo N, et al. CNS Neurol Disord Drug Targets. 2010 Nov;9(5):627-35. doi: 10.2174/187152710793361504. CNS Neurol Disord Drug Targets. 2010. PMID: 20632965 Free PMC article. Review. - Idiopathic pain and depression.
von Knorring L, Ekselius L. von Knorring L, et al. Qual Life Res. 1994 Dec;3 Suppl 1:S57-68. doi: 10.1007/BF00433378. Qual Life Res. 1994. PMID: 7866374 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical